Clinical Trials ActSection 13A
13A. Expedited review
(1) An application shall be eligible for expedited
review where it is designated as a Public Interest Clinical Trial.
(2) An application under subsection (1) shall be
submitted through the Public Interest Clinical Trial.
(3) The Council and the Ethics Committee shall
determine an application submitted under the expedited
review pathway within 30 days of receipt of a complete
application.
(4) The period specified in subsection (3) is
directory and its expiry shall not be construed as approval of
an application or as relieving the applicant of any requirement
under this Act.
(5) The Council may refuse expedited review
where –
(a) the application is incomplete;
(b) the proposed clinical trial raises
significant unresolved safety concerns; or
(c) the Council considers that full review
is required in the interests of the health,
welfare, safety or protection of subjects.
(6) The refusal of expedited review shall not prevent
an application from being considered under the ordinary
review pathway.
324 Acts 2026
(k) in section 14, in subsection (2), by deleting the word “sponsor”
and replacing it by the word “applicant”;
(l) in section 15 –
(i) in subsection (1), by deleting the word “sponsor” and
replacing it by the words “trial licence holder”;
(ii) in subsection (4), by deleting the word “sponsor” and
replacing it by the words “trial licence holder”;
(iii) in subsection (5), by deleting the word “sponsor” and
replacing it by the words “trial licence holder”;
(m) by inserting, after section 19, the following new section –